These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 28210207)

  • 21. Innovative Therapeutic Potential of Cannabinoid Receptors as Targets in Alzheimer's Disease and Less Well-Known Diseases.
    Páez JA; Campillo NE
    Curr Med Chem; 2019; 26(18):3300-3340. PubMed ID: 29484980
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The development of cannabinoid CBII receptor agonists for the treatment of central neuropathies.
    Rivers JR; Ashton JC
    Cent Nerv Syst Agents Med Chem; 2010 Mar; 10(1):47-64. PubMed ID: 20236042
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Upregulation of the cannabinoid CB2 receptor in environmental and viral inflammation-driven rat models of Parkinson's disease.
    Concannon RM; Okine BN; Finn DP; Dowd E
    Exp Neurol; 2016 Sep; 283(Pt A):204-12. PubMed ID: 27317300
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Endocannabinoid System: A Multi-Facet Therapeutic Target.
    Kaur R; Ambwani SR; Singh S
    Curr Clin Pharmacol; 2016; 11(2):110-7. PubMed ID: 27086601
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular and functional interaction between GPR18 and cannabinoid CB
    Reyes-Resina I; Navarro G; Aguinaga D; Canela EI; Schoeder CT; Załuski M; Kieć-Kononowicz K; Saura CA; Müller CE; Franco R
    Biochem Pharmacol; 2018 Nov; 157():169-179. PubMed ID: 29870711
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic potential of α7 nicotinic receptor agonists to regulate neuroinflammation in neurodegenerative diseases.
    Foucault-Fruchard L; Antier D
    Neural Regen Res; 2017 Sep; 12(9):1418-1421. PubMed ID: 29089979
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuroinflammation: A Critical Factor in Neurodegenerative Disorders.
    Suleiman Khoury Z; Sohail F; Wang J; Mendoza M; Raake M; Tahoor Silat M; Reddy Bathinapatta M; Sadeghzadegan A; Meghana P; Paul J
    Cureus; 2024 Jun; 16(6):e62310. PubMed ID: 39006715
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dementia of Alzheimer's disease and other neurodegenerative disorders--memantine, a new hope.
    Sonkusare SK; Kaul CL; Ramarao P
    Pharmacol Res; 2005 Jan; 51(1):1-17. PubMed ID: 15519530
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia.
    Calabrese V; Lodi R; Tonon C; D'Agata V; Sapienza M; Scapagnini G; Mangiameli A; Pennisi G; Stella AM; Butterfield DA
    J Neurol Sci; 2005 Jun; 233(1-2):145-62. PubMed ID: 15896810
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cannabinoid receptors and endocannabinoids: role in neuroinflammatory and neurodegenerative disorders.
    Bisogno T; Di Marzo V
    CNS Neurol Disord Drug Targets; 2010 Nov; 9(5):564-73. PubMed ID: 20632970
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modulation of Astrocyte Activity by Cannabidiol, a Nonpsychoactive Cannabinoid.
    Kozela E; Juknat A; Vogel Z
    Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28788104
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Role of Cannabinoid Type 2 Receptors in Parkinson's Disease.
    Basile MS; Mazzon E
    Biomedicines; 2022 Nov; 10(11):. PubMed ID: 36428554
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Dynamic Role of Microglia and the Endocannabinoid System in Neuroinflammation.
    Young AP; Denovan-Wright EM
    Front Pharmacol; 2021; 12():806417. PubMed ID: 35185547
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ginsenoside Rb1 as a neuroprotective agent: A review.
    Ahmed T; Raza SH; Maryam A; Setzer WN; Braidy N; Nabavi SF; de Oliveira MR; Nabavi SM
    Brain Res Bull; 2016 Jul; 125():30-43. PubMed ID: 27060612
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuroprotection in Oxidative Stress-Related Neurodegenerative Diseases: Role of Endocannabinoid System Modulation.
    Paloczi J; Varga ZV; Hasko G; Pacher P
    Antioxid Redox Signal; 2018 Jul; 29(1):75-108. PubMed ID: 28497982
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic potential of cannabinoids in the treatment of neuroinflammation associated with Parkinson's disease.
    Little JP; Villanueva EB; Klegeris A
    Mini Rev Med Chem; 2011 Jun; 11(7):582-90. PubMed ID: 21699489
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Roles of the Cannabinoid System in the Basal Ganglia in Parkinson's Disease.
    Wang M; Liu H; Ma Z
    Front Cell Neurosci; 2022; 16():832854. PubMed ID: 35264932
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting toll-like receptor 4 to modulate neuroinflammation in central nervous system disorders.
    Leitner GR; Wenzel TJ; Marshall N; Gates EJ; Klegeris A
    Expert Opin Ther Targets; 2019 Oct; 23(10):865-882. PubMed ID: 31580163
    [No Abstract]   [Full Text] [Related]  

  • 39. Cannabinoid receptor CB2 is expressed on vascular cells, but not astroglial cells in the post-mortem human Huntington's disease brain.
    Dowie MJ; Grimsey NL; Hoffman T; Faull RL; Glass M
    J Chem Neuroanat; 2014 Sep; 59-60():62-71. PubMed ID: 24978314
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The endocannabinoid system in Huntington's disease.
    Pazos MR; Sagredo O; Fernández-Ruiz J
    Curr Pharm Des; 2008; 14(23):2317-25. PubMed ID: 18781982
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.